Document Detail

The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema.
MedLine Citation:
PMID:  9865617     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The carbonic anhydrase inhibitor acetazolamide (AZM) reduces macular oedema in some patients with retinitis pigmentosa. To better understand the oedema-reducing effect of AZM, the effect of AZM on passive permeability and active transport of fluorescein across the blood-retina barrier was studied in patients with retinitis pigmentosa and varying degrees of macular oedema. METHOD: The selection of patients was based on an introductory examination including vitreous fluorometry for qualitative assessment of the vitreous. Macular oedema was graded by fluorescein angiographic leakage. The effect of AZM on the transport properties of the blood-retina barrier was determined by differential spectrofluorometry, in a randomised, double-masked, cross-over study, comprising 2 weeks' treatment with AZM (500 mg/day) and 2 weeks' treatment with placebo. The penetration ratio, defined as the ratio between vitreous concentration 3 mm in front of the retina and the plasma integral, was determined for fluorescein and its metabolite fluorescein glucuronide at 30-60 min and at 120 min after fluorescein injection. Passive permeability and unidirectional permeability in the direction vitreous to blood, due to outward active transport of fluorescein, were determined in those cases where the curves for vitreous concentration of fluorescein could be fitted to a mathematical model. Visual acuity was tested by use of ETDRS standard logarithmic charts. RESULTS: Twenty-two patients volunteered to participate in the study. Signs of significant vitreous detachment/liquefaction caused the exclusion of ten patients after the introductory examination. Nine patients with approximately intact vitreous and varying degrees of oedema completed the cross-over study. AZM treatment was related to a decrease in the penetration ratio of 21% for fluorescein (P=0.01) and of 22% for fluorescein glucuronide (P=0.004). Passive permeability and unidirectional permeability were determined in seven patients. AZM caused a decrease of 27% in the passive permeability of fluorescein (from 1.1 x 10(1) nm/s, P=0.031), and a 95% increase in unidirectional permeability of fluorescein (from 1.2 x 10(2) nm/s, P=0.047). AZM led to a reduction in the grade of macular oedema as determined by fluorescein angiography in three out of seven patients. Only small improvements (< or =5 letters) in visual acuity were noted. CONCLUSION: The present study indicates that the oedema-reducing effect of AZM is due to decreased leakage and stimulated active transport across the blood-retina barrier.
B Moldow; B Sander; M Larsen; C Engler; B Li; T Rosenberg; H Lund-Andersen
Related Documents :
3191077 - Retinal circulation during a spontaneous rise of intraocular pressure.
12084747 - Retrobulbar circulation in myopic patients with or without myopic choroidal neovascular...
18568887 - Reliability of different image analysis methods for scanning laser doppler flowmetry.
16936107 - Hemorheologic abnormalities associated with hiv infection: in vivo assessment of retina...
6959257 - Production of leucocyte poor blood. a comparison of five different methods.
24849667 - Changes in cortical microvasculature during misery perfusion measured by two-photon las...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  236     ISSN:  0721-832X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  1998 Dec 
Date Detail:
Created Date:  1999-03-16     Completed Date:  1999-03-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  881-9     Citation Subset:  IM    
University of Copenhagen, Herlev Sygehus, Department of Ophthalmology, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetazolamide / therapeutic use*
Biological Transport, Active / drug effects
Blood-Retinal Barrier / drug effects*
Carbonic Anhydrase Inhibitors / therapeutic use*
Cross-Over Studies
Double-Blind Method
Fluorescein / diagnostic use,  pharmacokinetics*
Fluorescein Angiography
Fluoresceins / diagnostic use,  pharmacokinetics
Fundus Oculi
Macular Edema / drug therapy,  etiology,  metabolism*
Middle Aged
Retina / metabolism*
Retinitis Pigmentosa / complications,  drug therapy,  metabolism*
Reg. No./Substance:
0/Carbonic Anhydrase Inhibitors; 0/Fluoresceins; 2321-07-5/Fluorescein; 59-66-5/Acetazolamide; 74804-84-5/fluorescein glucuronide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cloning and characterization of the gene encoding a new DNA methyltransferase from Neisseria gonorrh...
Next Document:  Effect of exposure to balanced salt solution upon the hardness of the crystalline lens.